Physician profile

Jack R Ross

Family Medicine · Columbus, GA

NPI 1497779714

$2,891.40

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novo Nordisk INC $474.27 2019-2021
Astrazeneca Pharmaceuticals LP $361.86 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $325.41 2019-2021
Sanofi-Aventis U.S. LLC $284.16 2019-2021
Janssen Pharmaceuticals, INC $248.55 2019-2021
Pfizer INC. $245.99 2019-2020
Lilly USA, LLC $210.95 2019-2021
Glaxosmithkline, LLC. $167.23 2019-2021
Amgen INC. $134.07 2019-2020
Merck Sharp & Dohme LLC $86.07 2019-2020
Astellas Pharma US INC $80.54 2019-2021
Amarin Pharma, INC. $44.64 2019
Vivus LLC $33.42 2019
Novartis Pharmaceuticals Corporation $31.84 2019-2020
Abbvie INC. $27.33 2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $26.91 2019
Zyla Life Sciences, INC. $26.47 2019
Braemar Manufacturing, LLC $20.84 2019
Biohaven Pharmaceuticals, INC. $16.64 2021
Alexion Pharmaceuticals, INC. $16.20 2019
Abbott Laboratories $14.85 2019
Radius Health, INC. $13.16 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jack R Ross

$2,891.40

in general payments reported 2019-2025

Years
2019-2021
Top company
Novo Nordisk INC

https://glasscript.com/doctor/294149/jack-r-ross

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.